Regulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific Officer
Regulus Therapeutics (Nasdaq: RGLS) announced the appointment of Denis Drygin, Ph.D., as Chief Scientific Officer effective August 3, 2020. Dr. Drygin brings nearly 20 years of experience in drug discovery and development, previously serving at Pimera and Cylene Pharmaceuticals. CEO Jay Hagan expressed confidence in Dr. Drygin's expertise to enhance Regulus' innovative microRNA therapeutics pipeline. This strategic hire aims to strengthen the company's position in addressing high unmet medical needs in various indications.
- Denis Drygin's extensive experience in drug discovery and development may provide fresh insight and leadership.
- The appointment is expected to bolster Regulus' microRNA therapeutics pipeline, positioning the company for potential growth.
- Concerns about potential continuity and experience gaps due to the leadership transition.
LA JOLLA, Calif., Aug. 3, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Denis Drygin, Ph.D., as Chief Scientific Officer effective August 3, 2020.
"We are excited to announce the addition of Denis to the Regulus leadership team," said Jay Hagan, CEO of Regulus. "Denis brings nearly 20 years of drug discovery and development experience to the company, working with both small molecule and neucleic acid based therapeutics. Denis will be a tremendous asset to our company as we leverage our platform technology and build our pipeline."
Dr. Drygin joins Regulus from Pimera, where he was founder and Vice President of Research and Development since 2013. Prior to Pimera, Denis served with Cylene Pharmaceuticals for over 8 years, most recently as Vice President of Biology where he led the initiation of a Phase I clinical trial for CX-5461, supervising development and translation of predictive and prognostic biomarkers. Prior to this, he led biology operations where he oversaw preclinical development of CX-5461, a first-in-class selective inhibitor of Pol I, and the preclinical development program for Silmitasertib, a first-in-class oral inhibitor of Ser/Thr kinase CK2. Prior to Cylene, Denis completed his post-doctoral work at Ionis Pharmaceuticals, where he served as lead scientist on several projects to investigate the pharmacology and toxicology of antisense oligonucleotides (ASOs).
"With microRNA based therapeutics being on the cusp of shifting the treatment paradigm for multiple indications with high unmet medical need, Regulus is uniquely positioned to become a pioneer in bringing new therapeutic options to the patients," said Dr. Drygin. "I am truly privileged to join the company at such an exciting time."
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in La Jolla, CA.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the potential of microRNA therapeutics. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs, and feedback from the FDA. In addition, while Regulus expects the COVID-19 pandemic to adversely affect its business operations and financial results, the extent of the impact on Regulus' ability to achieve its preclinical and clinical development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
View original content to download multimedia:http://www.prnewswire.com/news-releases/regulus-therapeutics-appoints-denis-drygin-phd-as-chief-scientific-officer-301104281.html
SOURCE Regulus Therapeutics Inc.
FAQ
What is the significance of Denis Drygin's appointment as Chief Scientific Officer at Regulus Therapeutics?
How might Denis Drygin's experience impact Regulus Therapeutics' R&D efforts?
What challenges could Regulus Therapeutics face after the appointment of a new Chief Scientific Officer?
When did Denis Drygin officially join Regulus Therapeutics?
